To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Laboratory | Molecular mechanisms
The Molecular Engineering for Health Unit (SIMoS) carries out research focused on the identification and pre-clinical development of bioactive molecules (small molecules but mostly peptides and proteins) isolated from natural or synthetic libraries. Their developments include the in-vitro and in-vivo characterization of their functional properties, the molecular and structural analysis of their mode of action and the optimization of their druggability by chemical/biological engineering aiming to increase their potency and selectivity or to suppress their immunogenicity.
We developed original chemical and enzymatic strategies for the site-selective modification of proteins in vitro and in vivo. By relying on these approaches, we design new chemical tools such as protein-drug conjugates and chemical probes with potential diagnostic and therapeutic applications in various pathologies including cancer, inflammation and neurodegenerative diseases.
We develop broad-spectrum inhibitors of bacterial toxins that interfere with the intracellular trafficking machinery. As a result, these inhibitors have also antiviral, anti-intracellular bacteria and anti-parasitic activities. We also develop a fragment of the diphtheria toxin as an inhibitor of HB-EGF for the treatment of rapidly progressive glomerulonephritis, a rare kidney disease.
The team focuses its research on the mechanisms and early stage evaluation of immunogenicity of therapeutic proteins and antibodies and on the engineering of antibodies using Yeast Surface Display. Our main objective is to develop new antibody-related molecules with high affinity, controlled selectivity and low immunogenicity.
The goal of our research is to exploit the huge diversity of peptides present in venoms to identify, pharmacologically characterize and optimize ligands that interact selectively with receptors and ion channels and that can be develop as theranostic agents. In addition, we study the mode of action of emergent marine neurotoxins and develop detection systems able to identify them.
We performed digital autoradiographic analyses of radioactive molecules in order to characterize their pharmacokinetic properties and in-vivo biodistribution in the context of their pre-clinical studies. In addition, we determine in various animal models the proof of concept of the in-vivo functional properties of lead compounds developed in the Unit.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.